Skip to content
OpenCapital
Get started

Cytokinetics CYTK Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$912M+0.6%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
——

Other financials

Income statement

See full
Revenue$19.4M+1,126%
Operating income-$183.6M-18.0%
Net income-$206.0M-27.7%
EPS (diluted)-$1.67-22.8%

Balance sheet

See full
Cash & equivalents$129.8M+76.2%
Total debt$418.2M+75.8%
Total equity-$826.6M-210%
Total assets$1.3B+0.7%

Cash flow

See full
Operating cash flow-$145.5M-10.5%
CapEx$5.9M+4.7%
Free cash flow-$151.4M-10.3%

Valuation

See full
Market cap$10.7B+70.6%
Enterprise value$10.98B+70.7%
P/S101.1×-225×

Profitability

See full
Operating margin-605.1%-268pp
Net margin-784%-337pp
FCF margin-518.8%-223pp

Returns & leverage

See full
Return on equity-337.6%—
Debt / equity2.2×—
Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytokinetics's available for sale securities debt securities current?
Cytokinetics (CYTK) reported available for sale securities debt securities current of $688.71M in Q1 2026.
How has Cytokinetics's available for sale securities debt securities current changed year-over-year?
Cytokinetics's available for sale securities debt securities current decreased by 20.3% year-over-year, from $864.54M to $688.71M.
What is the long-term trend for Cytokinetics's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Cytokinetics's available for sale securities debt securities current has grown at a 14.8% compound annual growth rate (CAGR), from $381.08M to $759.7M.